youtube_live
Q3 2026 earnings • released • EPS beat +8.03% • Revenue miss -10.71%
See resultschevron_right
EBS:NYSE
Emergent Biosolutions Inc
$6.06
arrow_upward
+3.59%(+0.21) 1D
$5.97
arrow_downward
-1.49% (-0.090)bedtimeAfter hours
Closed: Nov 6, 4:00:03 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EBS...
Open
$5.79
High
$6.07
Low
$5.78
Mkt. cap
311.58M
Avg. vol.
1.12M
Volume
1.00M
52-wk high
$14.06
52-wk low
$4.36
EPS
-$3.51
Beta
2.37
Shares outstanding
51.42M
No. of employees
900
Open
$5.79
High
$6.07
Low
$5.78
Mkt. cap
311.58M
Avg. vol.
1.12M
Volume
1.00M
52-wk high
$14.06
52-wk low
$4.36
EPS
-$3.51
Beta
2.37
Shares outstanding
51.42M
No. of employees
900
News stories
From web sources and news partners
Seeking Alpha
·
1 day ago
Emergent BioSolutions: A Turnaround Still Waiting For Consistent Execution (NYSE:EBS)
Profile
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded. Wikipedia
About Emergent Biosolutions Inc
CEORobert G. Kramer Sr. | Joseph C. Papa
Employees900
FoundedSep 5, 1998
HeadquartersRockville, Maryland, United States
SectorHealth Care
IndustryBiotechnology
Websiteemergentbiosolutions.com